Processa Pharmaceuticals, INC Form 4 insider transactions

Chief Business and Strategy Officer Patrick Lin acquired 1,369 shares of Processa Pharmaceuticals common stock.

Chief Administrative Officer Wendy Guy acquired 1,583 shares of Processa Pharmaceuticals common stock at $2.97 per share.

Processa Pharmaceuticals CFO Russell Skibsted acquired 1,984 shares of common stock at $2.97 per share.

Processa Pharmaceuticals CEO George Ng acquired 1,843 shares of common stock in an open market transaction.

Processa Pharmaceuticals reports a Form 4 filing detailing a Chief Development Officer's acquisition of common stock.

David Young, President of R&D at Processa Pharmaceuticals, acquired 1,706 shares of common stock at $2.69 per share.

Processa Pharmaceuticals CFO Russell Skibsted acquired 2,190 shares of common stock at $2.69 per share.

Processa Pharmaceuticals CEO George Ng acquired 2,034 shares of common stock at a price of $2.69 per share.

Chief Business and Strategy Officer Patrick Lin acquired 1,511 shares of Processa Pharmaceuticals common stock.

Chief Administrative Officer Wendy Guy acquired 1,748 shares of Processa Pharmaceuticals common stock at $2.69 per share.

Chief Development Officer Sian Bigora acquired 1,986 shares of Processa Pharmaceuticals common stock at $2.69 per share.

Processa Pharmaceuticals CEO George Ng acquired 1,843 shares of common stock at $2.97 per share.

Processa Pharmaceuticals CEO George Ng acquired 2,136 shares of common stock at $2.535 per share.

David Young, President of R&D at Processa Pharmaceuticals, acquired 1,545 shares of common stock on April 15, 2026.

CEO George Ng acquired 1,843 shares of Processa Pharmaceuticals, Inc. common stock at $2.97 per share.

Chief Business and Strategy Officer Patrick Lin acquired 1,369 shares of Processa Pharmaceuticals common stock.

Chief Administrative Officer Wendy Guy acquired 1,583 shares of Processa Pharmaceuticals common stock at $2.97 per share.

Chief Development Officer Sian Bigora acquired 1,799 shares of Processa Pharmaceuticals common stock at $2.97 per share.

Processa Pharmaceuticals CFO Russell Skibsted acquired 1,984 shares of common stock at $2.97 per share.

Processa Pharmaceuticals, Inc. reports a transaction where Director James R. Neal acquired 789 shares of common stock.

Processa Pharmaceuticals' President of R&D, David Young, plans to acquire 1,810 shares of common stock at $2.535 per share under a 10b5-1 plan.

Processa Pharmaceuticals' CFO Russell Skibsted purchased 2,324 shares of common stock, signaling management confidence.

Processa Pharmaceuticals Director Geraldine Pannu acquired 2,072 shares of common stock at $2.535 per share under a pre-arranged trading plan.

Processa Pharmaceuticals CEO George Ng reported the purchase of 2,136 shares of common stock at $2.535 per share.

Processa Pharmaceuticals' Chief Business Strategy Officer, Patrick Lin, acquired 1,603 shares of common stock.

Processa Pharmaceuticals' Chief Administrative Officer, Wendy Guy, increased her direct stake in the company by purchasing 1,854 shares of common stock.

Processa Pharmaceuticals' Chief Development Officer, Sian Bigora, acquired 2,107 shares of common stock at $2.535 per share.

Processa Pharmaceuticals Director Khoso Baluch plans to acquire 2,269 shares of common stock at $2.535 per share on March 31, 2026.

David Young, a Director and President of Research & Development at Processa Pharmaceuticals, reported the distribution of 49 vested restricted shares of common stock.

Processa Pharmaceuticals' Chief Business Strategy Officer, Patrick Lin, reported the distribution of 193 vested restricted shares of common stock.